Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名:AY 22989,NSC-2260804

Rapamycin (Sirolimus)化学構造

分子量(MW):914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

サイズ 価格(税別)  
JPY 50796.00
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中の使用例(64)

カスタマーフィードバック(13)

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明 Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
ターゲット
mTOR [1]
(HEK293 cells)
~0.1 nM
体外試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NXzWUXVuS3m2b4TvfIlkKEG|c3H5 MYOxNEBvVQ>? NUfMUYJKPzJiaB?= MnToSG1UVw>? M2P6[HBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> MVWyOFkxODh5Mx?=
HT-29 NYHNb3pLS3m2b4TvfIlkKEG|c3H5 MnTSNVAhdk1? NGW1bYc4OiCq M1fJO2ROW09? MnPCVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 MUSyOFkxODh5Mx?=
HT-29 M1vpemN6fG:2b4jpZ{BCe3OjeR?= MXqxNEBvVQ>? M1nMVlczKGh? NWDIbo5WTE2VTx?= M{jnb3BwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NY\5foM5OjR7MEC4O|M>
PC3 MXvLbY5ie2ViQYPzZZk> MmDGNVAxKG6P NUT3bmp6OSCq NIW3OINFVVOR M2rvN3BwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u MXqyNVk4QDZ6Mx?=
PC3 NYn6[GNmU2mwYYPlJGF{e2G7 NVTOWGhNOTByIH7N MkO0NUBp NGPTOo1FVVOR MlW2SI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MoDlNlE6Pzh4OEO=
PC3 NVHDNlBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LDTVEvPSEQvF2= M17EVVEhcA>? NYDtbYlnTE2VTx?= M2\MSmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= NHPKWmozOTl5OE[4Ny=>
HEK293 NF3KZ4RHfW6ldHnvckBCe3OjeR?= Mn:yNVAxKG6P M2HDXlghcA>? MU\EUXNQ M3zvbmlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= M2[4cVIyPTN7M{Cx
BT-20 NX;XPYU3U2mwYYPlJGF{e2G7 NHvsVmkzOCEQvF2= MnPnSG1UVw>? MmfLSI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25? M4PmVFIyOzV|NUWx
U937 NEfnRZRCdnSrYnHjeIVzcWGuIFHzd4F6 MXy1NEDPxE1? M1rL[lQ5KGh? MmTtSG1UVw>? MVHJcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN? NGXXVGEzOTF2MkGwOi=>
U937 MWrBcpRq[mGldHXybYFtKEG|c3H5 NWPwNJd[PTBizszN NE\NRWY1QCCq M2fQWWROW09? M37SRWRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhVUmSIIDyc5RmcW5vZHXmbYNq\W62IFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhUlJ|Mj2yJIlvKFV7M{egZ4VtdHN? M4jjZ|IyOTR{MUC2
U937 NGfiPZRCdnSrYnHjeIVzcWGuIFHzd4F6 MnrzOVAh|ryP MV[0PEBp MX3EUXNQ MnnNSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> MmryNlEyPDJzME[=
MCF-7 M1\pOWF2fG:yaHHnfUBCe3OjeR?= NGOzTHM{OCCwTR?= MYC0JIg> NVfHe4h7TE2VTx?= M1i0N2lv\HWlZYOgZZV1d3CqYXf5 MWiyNFAzQDF|NB?=
U87MG MlW5T4lv[XOnIFHzd4F6 MYexJO69VQ>? NXLJeG9FPiCq MWjEUXNQ NF:ze2JRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?= NFjmZ4QyQTh2OESwOC=>
U87MG MV\LbY5ie2ViQYPzZZk> NHHvU44yKM7:TR?= NIjhNmM3KGh? MUjEUXNQ NVX3e|c2WG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44> Mn30NVk5PDh2MES=
U87MG MnvET4lv[XOnIFHzd4F6 NHzL[mMyKM7:TR?= M1zsd|YhcA>? MYTEUXNQ NXT6V4Y4TG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= NGDSTZEyQTh2OESwOC=>
U87MG NULVcIREU2mwYYPlJGF{e2G7 NVv0SpFMOSEQvF2= NHL3d2w3KGh? NVTaNZJxTE2VTx?= Mn30SI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v MVWxPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb MXzBeZRweGijZ4mgRZN{[Xl? M2nJPFAvOiEQvF2= NUfTOllbOjRiaB?= MoOySG1UVw>? MnHlTY5lfWOnczDheZRweGijZ4m= NX22XVI1OTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 NX[5NWI6SXW2b4DoZYd6KEG|c3H5 NYPCWJhEOC5{IN88US=> MkLTNlQhcA>? NEjXUmlFVVOR NXLKbIw5UW6mdXPld{BifXSxcHjh[5k> M2rvT|E5OzlzOUS5
H4 MV3GeY5kfGmxbjDBd5NigQ>? NIfmOZYxNjJizszN NUTJOmViOjRiaB?= NVHsOWNSTE2VTx?= M13jb2lv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> NEjDNYMyQDB{NEW4OC=>
HeLa M4PzNGZ2dmO2aX;uJGF{e2G7 M4[4bVExOCCwTR?= MV6zOkBp M1HQdmROW09? NVP3dJpKUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? M4jFPVE4PTZ|M{i1
HeLa M2O1TmZ2dmO2aX;uJGF{e2G7 NUXOdI57OTByIH7N Mm[wN|YhcA>? M4P1cmROW09? MVjJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> MlG5NVc2PjN|OEW=
HeLa NYHyeppPTnWwY4Tpc44hSXO|YYm= NWTXbG5XOTByIH7N MlnjN|YhcA>? MoLOSG1UVw>? NHvNflRKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NFnzb3AyPzV4M{O4OS=>
SYF MWjGeY5kfGmxbjDBd5NigQ>? Mo\INVAxKG6P MYeyOEBp NF\mXGlFVVOR MXnJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= M2HG[VE4PTZ|M{i1
SYF NV;4PZBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[yNVAxKG6P MmHSNlQhcA>? NV;SflRMTE2VTx?= M2DLU2lv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO= NFfDW4wyPzV4M{O4OS=>
HEK293T MmO0RY51cX[rcnHsJGF{e2G7 NVP2XlkyOSCwTR?= NEm5UGw1KGR? M2HtSWROW09? NYjOOII{UW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> MUSxO|Q5PTVyMR?=
HEK293T M1fTdmFvfGm4aYLhcEBCe3OjeR?= NXX0S25zOSCwTR?= NYLKUmxoPCCm MknDSG1UVw>? MVnJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?= NITaS28yPzR6NUWwNS=>
PBMC MV;GeY5kfGmxbjDBd5NigQ>? MkSxNUBvVQ>? NV3N[YpROTRiZB?= M17DZ2ROW09? MVjS[YR2[2W|IFPDVlUh\GWwc3n0fS=> NVj5Z44yOTd2OEW1NFE>
PBMC NFTScGdHfW6ldHnvckBCe3OjeR?= NF\yWlkyKG6P MYWxOEBl M1f3fWROW09? NY[5OI1XTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? NV3K[mlIOTd2OEW1NFE>
HEK293 cells MVfLbY5ie2ViQYPzZZk> MmO5OVAhdk1? M3\GdlQ2KG2rbh?= NWe3SHc{TE2VTx?= MXfJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O M36yR|E4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NVW0XnhTTnWwY4Tpc44hSXO|YYm= NFT6R5IyODBibl2= NVjHUYhqPCCq MYjEUXNQ M3T2Tmlv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk MoHPNVcyOjh{NkK=
Human mixed lymphocyte NE[wO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnVOUBvVQ>? MVfEUXNQ Moj5TWM2OD1zLk[gcm0v MlzQNVYyQDV6NkW=
Lewis rat lymph node cells M{fRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvxOUDPxE1? M4[1fmROW09? M3juW2lEPTB;Mj62JO69VQ>? M37DN|E3OTh3OE[1
cells from the thymus of normal BALB/c mice MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxNEBvVQ>? NYfGVIZoPzJiaB?= NXq3eohLTE2VTx?= M{\FRmlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= M3j4W|ExODJzOUS4
MRK-nu-1 M{ToOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX2TWM2OD1yLki0OUBxVQ>? M1:5NHNCVkeHUh?=
OCUB-M MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCzcm5LUUN3ME21MlI1KHCP MlvTV2FPT0WU
SF539 M{\3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT6TWM2OD1zMT62JJBO M2KzNXNCVkeHUh?=
ES4 NWjjWIZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrK[|lKSzVyPUKxMlUheE1? Mnq5V2FPT0WU
RL95-2 NVnL[nNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ToZWlEPTB;MUC3JJBO M{X3cXNCVkeHUh?=
LC-2-ad NGnmeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7VS|JKSzVyPUSyN{BxVQ>? NH3qepVUSU6JRWK=
Daudi MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[wSHQ4UUN3ME20N|QheE1? MnvZV2FPT0WU
NTERA-S-cl-D1 M1TEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3XT2JKSzVyPUS0N{BxVQ>? MVHTRW5ITVJ?
OS-RC-2 NFrzWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzBPIJYUUN3ME22OVIheE1? NF32V3JUSU6JRWK=
VA-ES-BJ NF3LZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPRTWM2OD15MkOgdG0> NY\uc|BxW0GQR1XS
GR-ST NYS3NXhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTh2NjDwUS=> M1;YUXNCVkeHUh?=
SW872 NYjP[nNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULMRnExUUN3ME24OFYheE1? M1fH[XNCVkeHUh?=
NOS-1 MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLEW4ZKSzVyPUi3NUBxVQ>? NUnqeFFZW0GQR1XS
MC116 NGiwbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILJSplKSzVyPUm4OUBxVQ>? M{DSRnNCVkeHUh?=
NCI-H1355 NFvKPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwMEGgcm0> M2LYSnNCVkeHUh?=
RPMI-8226 NIjQbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vESWlEPTB;MT6xPUBvVQ>? NH7VeZlUSU6JRWK=
TE-15 MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHCTWM2OD1zLkO2JI5O NGG0bWdUSU6JRWK=
Ramos-2G6-4C10 NVLaO4ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TJXmlEPTB;MT60OkBvVQ>? NGH5PXBUSU6JRWK=
KU812 NHXFe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELQfZVKSzVyPUKuNFEhdk1? MUHTRW5ITVJ?
EW-1 NGS5VpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPVUWZKSzVyPUKuNVchdk1? NHHjSYhUSU6JRWK=
KS-1 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJwNEWgcm0> MVHTRW5ITVJ?
SK-LMS-1 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:2T3ZiUUN3ME2yMlQ6KG6P NUGwbo9UW0GQR1XS
TGBC1TKB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPKU3RKSzVyPUKuOlkhdk1? NEjMcoxUSU6JRWK=
TE-6 M3PmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PEWmlEPTB;Mj63O{BvVQ>? M{fze3NCVkeHUh?=
ETK-1 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnXTWM2OD1{LkiyJI5O NUPOdYZ7W0GQR1XS
BE-13 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XJZmlEPTB;Mj65PUBvVQ>? MlfTV2FPT0WU
A3-KAW M{O4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTERplOUUN3ME2yMlk6KG6P NYjkSZJtW0GQR1XS
TE-10 M17qfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\ROWNKSzVyPUOuN{BvVQ>? Ml:4V2FPT0WU
DOHH-2 M3XI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S5cWlEPTB;Mz6zOUBvVQ>? MWLTRW5ITVJ?
ES6 NFLHT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTNwNEOgcm0> NWf1dWd3W0GQR1XS
OPM-2 NVjuPJFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XVbmlEPTB;ND6xOUBvVQ>? NVXQbVBJW0GQR1XS
SH-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHOZ3RrUUN3ME20MlM1KG6P MYPTRW5ITVJ?
NB13 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP0bodSUUN3ME20MlM3KG6P MorsV2FPT0WU
HUTU-80 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzHTWM2OD12LkSyJI5O NGjNRY5USU6JRWK=
CCRF-CEM NIr6PYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz1d25KSzVyPUSuPVQhdk1? NHjFeYdUSU6JRWK=
TGBC24TKB MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTVwNUGgcm0> NHLWWYxUSU6JRWK=
697 M3O2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rsPWlEPTB;Nj6yPEBvVQ>? MXTTRW5ITVJ?
J-RT3-T3-5 NVPT[WxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnnTWM2OD14LkS2JI5O M4DBUHNCVkeHUh?=
KALS-1 NUSyWmRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTZwNU[gcm0> MVHTRW5ITVJ?
no-10 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDpOVBKSzVyPUeuNlkhdk1? NV33TVg2W0GQR1XS
SK-NEP-1 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTnXYNQUUN3ME24Mlc6KG6P MXrTRW5ITVJ?
L-540 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmixTWM2OD1zMD60NkBvVQ>? NVf1O5lnW0GQR1XS
JiyoyeP-2003 NHzYe|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFyLkm0JI5O MWLTRW5ITVJ?
HH Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[zTWpCUUN3ME2xNU4{QSCwTR?= MmLmV2FPT0WU
SR MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nEb2lEPTB;MUGuOFUhdk1? NUXCOXZKW0GQR1XS
QIMR-WIL NHHrXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzrRYZ[UUN3ME2xNU45PSCwTR?= M3vEb3NCVkeHUh?=
A4-Fuk M2PWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF|LkGyJI5O NHfmWnRUSU6JRWK=
CESS NHvwNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf2TWM2OD1zMz6xN{BvVQ>? MV3TRW5ITVJ?
KE-37 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF4LkC3JI5O NWjtSVNCW0GQR1XS
SK-UT-1 NV3qcnFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF4LkixJI5O MUnTRW5ITVJ?
SIG-M5 MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF5LkK1JI5O MWjTRW5ITVJ?
HT MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDvU2VGUUN3ME2xO{43KG6P NUK1WZNkW0GQR1XS
DEL NF3vfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP3TWM2OD1zNz65PUBvVQ>? MUTTRW5ITVJ?
SK-PN-DW MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjHVlNKSzVyPUKwMlI{KG6P MWHTRW5ITVJ?
RPMI-8402 NYi4[VFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrVNZZKSzVyPUKxMlc4KG6P NH3KbGZUSU6JRWK=
RPMI-6666 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ2LkSyJI5O M1;2N3NCVkeHUh?=
NCI-H720 NH3TRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DEcGlEPTB;MkWuOFEhdk1? MWHTRW5ITVJ?
EW-16 M17Kcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTQbGhKSzVyPUK2Mlg4KG6P MofkV2FPT0WU
BL-70 NF7xSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJ6LkO4JI5O M3HJ[3NCVkeHUh?=
SF126 M1\MXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUKxOFZlUUN3ME2zNE4{QCCwTR?= MU\TRW5ITVJ?
BC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTNzLkK2JI5O M3m5VnNCVkeHUh?=
MHH-PREB-1 NETmdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3yOVNKSzVyPUOyMlQ1KG6P NXq5OXZWW0GQR1XS
A101D NUDCZ4ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzJVXJKSzVyPUOyMlYzKG6P M1fiWnNCVkeHUh?=
NMC-G1 M3PiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTN|Lk[3JI5O NUjrdVB1W0GQR1XS
LB1047-RCC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnQTWM2OD1|ND62PUBvVQ>? NVexfnY3W0GQR1XS
EM-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13YbGlEPTB;M{iuOVMhdk1? NID5U5VUSU6JRWK=
COLO-684 MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:ySWlEPTB;M{muPEBvVQ>? M1\xO3NCVkeHUh?=
Becker MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfjTWM2OD12MT6wOUBvVQ>? NGq3[nZUSU6JRWK=
BL-41 NH\1ZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTR|Lk[2JI5O M2jNc3NCVkeHUh?=
MDA-MB-134-VI NVPtVINOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHO[ZZtUUN3ME20OE4xOiCwTR?= MWnTRW5ITVJ?
L-363 NIH1NmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fsSGlEPTB;NESuO|Mhdk1? Ml[xV2FPT0WU
ECC4 NEDTc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\ZTWM2OD12ND63PEBvVQ>? NFzJXm1USU6JRWK=
A388 NEHreZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTR2LkiyJI5O MmLmV2FPT0WU
HEL M{Hiemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7kTWM2OD12OT63PUBvVQ>? MWrTRW5ITVJ?
RKO MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn0TWM2OD13MD6yPUBvVQ>? MUHTRW5ITVJ?
KINGS-1 M3K0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37rVGlEPTB;NUGuOVUhdk1? M17DTHNCVkeHUh?=
EB-3 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnRTWM2OD13Mj62O{BvVQ>? NU\FOHJsW0GQR1XS
ARH-77 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDkfpFoUUN3ME21Nk45KG6P MYLTRW5ITVJ?
GCIY MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTV|LkS2JI5O NVrOOZBMW0GQR1XS
NCI-H1304 M3TBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPsTWM2OD13Nz6yNkBvVQ>? NHHycJRUSU6JRWK=
KARPAS-299 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW5Z|NRUUN3ME22NU45OiCwTR?= Ml\1V2FPT0WU
IA-LM Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnuxTWM2OD14OD6xN{BvVQ>? NVvOPHV7W0GQR1XS
GI-1 M3ni[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe4RXF[UUN3ME23NE4{QSCwTR?= MkKyV2FPT0WU
TE-11 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfRfY5KSzVyPUe3MlE4KG6P Mnu1V2FPT0WU
LS-411N M3zTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULQd4tzUUN3ME23O{42PyCwTR?= NVrBOmFoW0GQR1XS
no-11 M3r3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\VTWM2OD16Mz6yOEBvVQ>? MnvDV2FPT0WU
MV-4-11 NH\qfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TNZ2lEPTB;OEOuO|Mhdk1? NXjzT|FmW0GQR1XS
BV-173 MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XQbGlEPTB;OEOuPVchdk1? Mk\JV2FPT0WU
CMK M2f6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnpZXhKSzVyPUi0MlE3KG6P MorzV2FPT0WU
LC4-1 NVrVe41YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGybG5KSzVyPUi2MlczKG6P M1GwSHNCVkeHUh?=
COR-L279 M2TvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjpS5ozUUN3ME24O{4zPSCwTR?= MlLqV2FPT0WU
NCI-H209 M{XHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXvflhKSzVyPUi3MlQyKG6P M33xTXNCVkeHUh?=
Raji MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPQeXZFUUN3ME24PU44OiCwTR?= NXzzZWJtW0GQR1XS
LB996-RCC NX[5fGF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm3[IF3UUN3ME25N{41OyCwTR?= NES0bmNUSU6JRWK=
NCI-H526 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTMTWM2OD17Mz61PUBvVQ>? MXzTRW5ITVJ?
KGN NWXvdlVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfFTWM2OD17Nj6yPUBvVQ>? NVfKbHA3W0GQR1XS
MOLT-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTQV|huUUN3ME25Ok44QSCwTR?= M4HMfHNCVkeHUh?=
PF-382 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPaTWM2OD17Nj63PUBvVQ>? M4\SfnNCVkeHUh?=
BC-3 NFr6b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXtfJE5UUN3ME25PU4yQCCwTR?= MkDjV2FPT0WU
KARPAS-422 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[4c49KSzVyPUGwNk4xQSCwTR?= NXPFT4lnW0GQR1XS
SBC-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTiTWM2OD1zMEeuO|Uhdk1? M1m5[HNCVkeHUh?=
LC-1F MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFyOD6wOUBvVQ>? M1HZbnNCVkeHUh?=
GB-1 NFzpZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zafmlEPTB;MUC5MlAzKG6P M{HT[nNCVkeHUh?=
SNB75 MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXzTWM2OD1zMUmuOlkhdk1? Mk\1V2FPT0WU
BB65-RCC NEXwNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnENIpKSzVyPUGxPU46OyCwTR?= MXHTRW5ITVJ?
NCI-N87 M3rDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF{MT65PEBvVQ>? NHrmeZhUSU6JRWK=
IST-MEL1 MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfqfYFqUUN3ME2xNlIvOzhibl2= MmG2V2FPT0WU
HOP-62 NFLuU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\HWG81UUN3ME2xNlYvQDlibl2= Moi4V2FPT0WU
ACN MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OzdWlEPTB;MUS2Mlc2KG6P M2nxPXNCVkeHUh?=
DMS-114 NGHIcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF3MD62O{BvVQ>? MYrTRW5ITVJ?
MLMA M3znPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC3dmFKSzVyPUG1PU45QCCwTR?= NYi4[lBGW0GQR1XS
HT-144 M3nldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInk[FBKSzVyPUG2OU41OyCwTR?= NXy2XYdJW0GQR1XS
C2BBe1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj6TWM2OD1zNkeuO|Yhdk1? MmLLV2FPT0WU
L-428 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfaWlNQUUN3ME2xO|cvPyCwTR?= NY[zdlNtW0GQR1XS
DU-4475 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF6Nz62PEBvVQ>? MX3TRW5ITVJ?
CP67-MEL NVrFT2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOxcmZvUUN3ME2xPVkvOzhibl2= NXi4VpI{W0GQR1XS
MEG-01 M{f3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jQNWlEPTB;MkCxMlk3KG6P NFLYdWlUSU6JRWK=
IST-SL2 MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP1dYNGUUN3ME2yNFgvPjNibl2= NH;NOIpUSU6JRWK=
ES8 M17LWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLmTI94UUN3ME2yNlUvQTRibl2= MUHTRW5ITVJ?
COLO-800 M{Hxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW0TWM2OD1{M{WuNlghdk1? NVjNNoVtW0GQR1XS
MFH-ino NEPsT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ|NT64OEBvVQ>? NVvJcm15W0GQR1XS
OVCAR-4 NV:yeoVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ|Nz6yOEBvVQ>? MlfWV2FPT0WU
PSN1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnvWIdKSzVyPUK0Nk44OSCwTR?= MX\TRW5ITVJ?
EW-12 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ2Mz6xJI5O MnnwV2FPT0WU
HCC1599 MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rhRmlEPTB;Mk[xMlQ4KG6P NHqzOpFUSU6JRWK=
SJSA-1 MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj3TWM2OD1{N{GuOFYhdk1? MXTTRW5ITVJ?
ST486 NIjWZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LhWmlEPTB;Mkm2MlE1KG6P Mmm1V2FPT0WU
NOMO-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P0cmlEPTB;M{CwMlIyKG6P MYHTRW5ITVJ?
MN-60 NIDuSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37DOmlEPTB;M{C1MlMzKG6P MoO4V2FPT0WU
HCC1187 M{fsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DoPGlEPTB;M{C3MlI2KG6P NYjIbW1nW0GQR1XS
SW982 NH2ydldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNzND63OUBvVQ>? NVP3ZmN4W0GQR1XS
LB647-SCLC NELpVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTN{OD63NUBvVQ>? MoS2V2FPT0WU
HC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTFTWM2OD1|M{WuOUBvVQ>? M{LsdXNCVkeHUh?=
EHEB MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fLPGlEPTB;M{O3MlUzKG6P NE\BOVBUSU6JRWK=
TUR Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\WfWlEPTB;M{[zMlk2KG6P MoW3V2FPT0WU
LU-139 NWLwfm5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\HNJloUUN3ME2zO|gvODJibl2= M1HweXNCVkeHUh?=
NB1 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHs[5FKSzVyPUO4OE41PSCwTR?= NEXUNmxUSU6JRWK=
BB30-HNC NIT5XYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX1[2dKSzVyPUO4PE4{OiCwTR?= NEnzc49USU6JRWK=
HAL-01 NI\INoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PGe2lEPTB;M{i5MlI3KG6P MmO1V2FPT0WU
K5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomwTWM2OD12MUGuN|chdk1? MofBV2FPT0WU
MZ2-MEL NVi4e41QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRzMz62OEBvVQ>? NI\BOpdUSU6JRWK=
RXF393 NHPBVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\4bGlEPTB;NEG2MlQ2KG6P NF\ZcJRUSU6JRWK=
NCI-H1648 Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorXTWM2OD12MUeuOVMhdk1? MWTTRW5ITVJ?
TE-12 NF63N5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mke0TWM2OD12M{SuNlYhdk1? NIrZUldUSU6JRWK=
EoL-1- Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTR|Nz65PEBvVQ>? NYXZZoxlW0GQR1XS
JAR MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnlUGxVUUN3ME20N|gvPjJibl2= NWLZfJQxW0GQR1XS
DSH1 NUDhNFB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTR3OD65NUBvVQ>? MUTTRW5ITVJ?
NCI-H187 M{DISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTR4Mj64NUBvVQ>? Mm[5V2FPT0WU
HCE-4 M1O5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rYdGlEPTB;NEe3MlY3KG6P MlvQV2FPT0WU
8-MG-BA NUHvSmFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f0c2lEPTB;NUixMlUzKG6P NU\HSYRIW0GQR1XS
KLE M4Dhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvvTWM2OD13OEWuNkBvVQ>? MXXTRW5ITVJ?
KNS-42 NWW2c2NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqxTWM2OD13OE[uPFEhdk1? NHjKdGdUSU6JRWK=
MSTO-211H MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTZyOT63OEBvVQ>? NHuxZlhUSU6JRWK=
GDM-1 M1TEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTZzND6wPUBvVQ>? NXfDfmo3W0GQR1XS
TE-1 M1rBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHYTWM2OD14NE[uNVIhdk1? NFjVUm1USU6JRWK=
BT-474 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf0PJBKSzVyPU[0O{4xPiCwTR?= M{XIUHNCVkeHUh?=
KARPAS-45 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7ZTWM2OD14NEeuOkBvVQ>? NVPScGFCW0GQR1XS
MOLT-16 NH;oTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPrOlFKSzVyPU[0O{46OyCwTR?= MX7TRW5ITVJ?
KURAMOCHI NGTxe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmmzTWM2OD14NUeuOVEhdk1? M2LDe3NCVkeHUh?=
K-562 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnEUJJKSzVyPU[2PU42OSCwTR?= MnmwV2FPT0WU
EKVX NX\oVY5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTZ5Mj63NUBvVQ>? NYPq[mV2W0GQR1XS
GAK Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr0TWM2OD14N{WuN{BvVQ>? M4PVenNCVkeHUh?=
NCI-SNU-5 MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTZ7MD6wNUBvVQ>? MkXWV2FPT0WU
NCI-H2126 NFvQR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{flN2lEPTB;N{K2Mlg4KG6P M{Pve3NCVkeHUh?=
CTV-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHGUHdKSzVyPUe0OE46KG6P Mnu1V2FPT0WU
SW962 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTd2OD60OEBvVQ>? NHPFXIpUSU6JRWK=
MONO-MAC-6 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTd3Nj65N{BvVQ>? NHrKPGJUSU6JRWK=
NCI-H748 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\1[2lEPTB;N{W4Mlk6KG6P M1[ycXNCVkeHUh?=
NCI-H524 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Xtb2lEPTB;N{iwMlc{KG6P Mmj0V2FPT0WU
LS-123 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:3b2lEPTB;N{m1MlY6KG6P NWm1XWk{W0GQR1XS
NB7 NF:ybHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHraT4xKSzVyPUixOE4yPCCwTR?= MmrCV2FPT0WU
LS-1034 M{TMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LVWWlEPTB;OEK4Mlk5KG6P NH\HOXBUSU6JRWK=
TE-5 MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jPbmlEPTB;OEizMlU3KG6P NFKyb2lUSU6JRWK=
A704 M3WxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTh7OT6xOUBvVQ>? MXHTRW5ITVJ?
TK10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnCTWM2OD17MU[uNFMhdk1? M4\xSHNCVkeHUh?=
NCI-H345 NEToXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;3Opl7UUN3ME25OFMvOjJibl2= MWHTRW5ITVJ?
CGTH-W-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTwTWM2OD17NEiuNVMhdk1? MVfTRW5ITVJ?
NCI-H510A MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTl6NT6xNkBvVQ>? M3fTeXNCVkeHUh?=
NCI-H1963 NGTuW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwMEOyPVIh|ryP NILaW25USU6JRWK=
SCC-3 M2XK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLtTWM2OD1zLkCzOFE1KM7:TR?= MW\TRW5ITVJ?
EW-11 MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\zZ2J7UUN3ME2xMlA5PzR|IN88US=> NXm1c2VMW0GQR1XS
CPC-N NFHQfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe5R|FKSzVyPUGuNFg5KM7:TR?= M3nKbHNCVkeHUh?=
NCI-H1417 MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v0dmlEPTB;MT6xNlI3KM7:TR?= NGfqUVVUSU6JRWK=
DG-75 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NECydZBKSzVyPUGuNVYzQDVizszN MY\TRW5ITVJ?
HD-MY-Z NHjXeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7rVYJKSzVyPUGuNVY1OTZizszN MXzTRW5ITVJ?
ATN-1 NUD6fXc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrLTWM2OD1zLkK2NlA6KM7:TR?= NILpU4tUSU6JRWK=
KM-H2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnEcJZKSzVyPUGuNlY1ODhizszN MY\TRW5ITVJ?
NCI-H2081 M4m5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMk[2N|ch|ryP NIjqOIFUSU6JRWK=
HL-60 M3TR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFwMk[5OVkh|ryP NV;uOJlJW0GQR1XS
DB NWDiOnVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULaR4g3UUN3ME2xMlI4OjR{IN88US=> NG\yTHZUSU6JRWK=
NCI-H1522 M2[xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DT[2lEPTB;MT6yPFg5PyEQvF2= MkXzV2FPT0WU
AM-38 M1HQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnWdZBOUUN3ME2xMlMxPzJizszN MmT1V2FPT0WU
NCI-H446 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDOTWM2OD1zLkOyNVIyKM7:TR?= NIG2TWJUSU6JRWK=
SU-DHL-1 NFXJ[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwM{K4NFEh|ryP NV7rS5lLW0GQR1XS
NH-12 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7ENo5KSzVyPUGuN|Y{PzRizszN M12w[XNCVkeHUh?=
DMS-79 M{Xrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzaPIs1UUN3ME2xMlM3QDZ4IN88US=> MX7TRW5ITVJ?
NCI-H716 M3:1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLWTWM2OD1zLkO4PVg3KM7:TR?= NIflbmlUSU6JRWK=
ML-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrjNZkzUUN3ME2xMlQyPTJ7IN88US=> NV;O[llmW0GQR1XS
NB10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwNE[2N|Ih|ryP MUDTRW5ITVJ?
ONS-76 NX3xTmoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\3TWM2OD1zLkWzOVY6KM7:TR?= Mk\vV2FPT0WU
LOUCY NWTnWppMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXqTWM2OD1zLkW0OlU4KM7:TR?= NH7NVWNUSU6JRWK=
SCLC-21H NFPU[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUD1PHNWUUN3ME2xMlU5PTh{IN88US=> NVq5XW04W0GQR1XS
TGW NHXtUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwNkO5O|Uh|ryP NIHuW|NUSU6JRWK=
LXF-289 NV3I[o5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm2foVKSzVyPUGuO|MzPjhizszN MYTTRW5ITVJ?
BB49-HNC M4nzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPITWM2OD1zLkezOVg3KM7:TR?= NGHXZoxUSU6JRWK=
NCI-H747 MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T6ZWlEPTB;MT63OVM1PiEQvF2= M1v3fXNCVkeHUh?=
LU-165 M3[2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO1cVRKSzVyPUGuPFQ6QDZizszN NYDsbm17W0GQR1XS
OMC-1 NWf3fHRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf3R2FKSzVyPUGuPVUxPjZizszN MYDTRW5ITVJ?
RCC10RGB M1fNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHftdHlKSzVyPUGuPVU5OTdizszN NEjoUHRUSU6JRWK=
SW684 M3z3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFwOU[wPVkh|ryP NHLFemJUSU6JRWK=
TE-8 M1n3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnqeWJpUUN3ME2yMlA2PTV7IN88US=> MlL6V2FPT0WU
SK-N-DZ M4XKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fMO2lEPTB;Mj6xN|I4PCEQvF2= NFzIN|JUSU6JRWK=
EVSA-T NYfvT|VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonHTWM2OD1{LkG3N|E2KM7:TR?= Ml\1V2FPT0WU
KASUMI-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJwMUi4NVUh|ryP M3nmfXNCVkeHUh?=
NKM-1 NYjwblBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPmd4VmUUN3ME2yMlI2PDd{IN88US=> NVu5T2tSW0GQR1XS
CAL-148 NE\CNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwM{O2NVQh|ryP Mme4V2FPT0WU
NCI-H64 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;KR|lRUUN3ME2yMlM1OjN{IN88US=> NWfYUm1[W0GQR1XS
KNS-81-FD NVe4ZmJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O2R2lEPTB;Mj6zOlYzKM7:TR?= NHTrZZJUSU6JRWK=
KM12 NGfzZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nHb2lEPTB;Mj60NFg{QSEQvF2= NXq2eIhmW0GQR1XS
SW954 MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGOxV|JKSzVyPUKuOFc4PzlizszN MoPSV2FPT0WU
NCI-H1395 M3jJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vlUWlEPTB;Mj61NlY1PSEQvF2= MYHTRW5ITVJ?
DJM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTnNW5KSzVyPUKuOlA3OyEQvF2= NEfz[5pUSU6JRWK=
COLO-668 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;JTWM2OD1{LkiyOlk2KM7:TR?= M16xU3NCVkeHUh?=
NCI-H1436 NHrFXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPCTWM2OD1{Lki1OlE2KM7:TR?= MVrTRW5ITVJ?
LB2241-RCC M3e3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrkTWM2OD1{Lki2PFM6KM7:TR?= NHvsRYZUSU6JRWK=
GT3TKB MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G2RWlEPTB;Mj64PVA2PSEQvF2= NXjUNGoyW0GQR1XS
COLO-824 M1GzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXGTWM2OD1{Lki5O|Y5KM7:TR?= NF[2b3lUSU6JRWK=
ES1 NX;NfGk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XnRmlEPTB;Mj64PVg4QSEQvF2= MlfJV2FPT0WU
LB771-HNC M3HSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NESxWZpKSzVyPUKuPVA6PDZizszN MYTTRW5ITVJ?
GI-ME-N MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;MTWM2OD1|LkCwPVA1KM7:TR?= MmiwV2FPT0WU
NALM-6 NFK2WXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDtZ|dKSzVyPUOuNFA6OzNizszN MVTTRW5ITVJ?
LU-134-A NVPXSFgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\0W3Q1UUN3ME2zMlA2PDJ3IN88US=> MXrTRW5ITVJ?
DMS-153 NFLuTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\KUpo4UUN3ME2zMlA2QDJ2IN88US=> NGHjdIRUSU6JRWK=
MZ1-PC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jZZ2lEPTB;Mz6wPVA4QCEQvF2= MUfTRW5ITVJ?
NCI-H1155 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTNwMUG2NUDPxE1? M3rWUHNCVkeHUh?=
CAS-1 NVPVbZZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHRbFRKSzVyPUOuNVM4ODdizszN NHj3eYNUSU6JRWK=
D-502MG NYjPZ2Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjQeHI4UUN3ME2zMlE1OzlizszN MWfTRW5ITVJ?
NCI-H2141 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofxTWM2OD1|LkG3OFUzKM7:TR?= NEK5eXpUSU6JRWK=
NB6 NVTHU3NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrWdY9KSzVyPUOuNVgzPTlizszN M4PzWXNCVkeHUh?=
NCCIT M4jTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmewTWM2OD1|LkKxPFA6KM7:TR?= NYrnXJFyW0GQR1XS
NB69 NHvCXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwM{G4PVEh|ryP M2fmSHNCVkeHUh?=
JVM-2 M17kT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrmRXJ3UUN3ME2zMlM3PDN|IN88US=> NEP4RmpUSU6JRWK=
K052 M4L1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;iVlBKSzVyPUOuN|c6PjhizszN NGjEdJBUSU6JRWK=
HCC2157 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXlbWRKSzVyPUOuOVMzOjhizszN MUfTRW5ITVJ?
KMOE-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;ZS2lEPTB;Mz61OFI1OiEQvF2= NFOxdnJUSU6JRWK=
SF268 NYjEcngzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrFTWM2OD1|LkexOVU1KM7:TR?= MonWV2FPT0WU
CHP-126 NYTwc2dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS1N295UUN3ME2zMlc3PDV6IN88US=> NGDyWYtUSU6JRWK=
CP66-MEL MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX2XIZKSzVyPUOuO|kxQTRizszN MnK1V2FPT0WU
NCI-H69 NIHS[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzX[nFHUUN3ME20MlAyQTN4IN88US=> MkTXV2FPT0WU
A253 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGwTWM2OD12LkCyNVAyKM7:TR?= MnvrV2FPT0WU
NB14 NWHoZ|RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHx[oczUUN3ME20MlExPDd7IN88US=> M1nlS3NCVkeHUh?=
NCI-H1694 NYOyelMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwMUOxNVIh|ryP M{[yUXNCVkeHUh?=
NCI-H2196 MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O2Z2lEPTB;ND6xO|E3QSEQvF2= NI[1SHhUSU6JRWK=
TE-9 NWLPTVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PCbGlEPTB;ND6xO|U5OiEQvF2= MmPUV2FPT0WU
D-283MED M124[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTRwMUi4OEDPxE1? NX\hbow3W0GQR1XS
OCI-AML2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknDTWM2OD12LkG5OFg6KM7:TR?= MoDzV2FPT0WU
D-263MG M2j6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXzfmhjUUN3ME20MlIzQTZzIN88US=> M16w[HNCVkeHUh?=
MPP-89 NEHmVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnMRVYyUUN3ME20MlI4OzB2IN88US=> NX\mb2VMW0GQR1XS
LAMA-84 MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDiOoNrUUN3ME20MlMxPDJzIN88US=> MXjTRW5ITVJ?
LB373-MEL-D M3[4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjYZWxmUUN3ME20MlM3Pzh7IN88US=> NITUUoVUSU6JRWK=
UACC-257 MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXNTWM2OD12LkO5OVM1KM7:TR?= NWfLW3F6W0GQR1XS
MC-CAR NHjQ[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XvW2lEPTB;ND60N|k6KM7:TR?= NUD1OJFCW0GQR1XS
COLO-320-HSR MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36yNWlEPTB;ND60OFQzPyEQvF2= NX;XXYxVW0GQR1XS
P30-OHK M2PCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfKd5ZKSzVyPUSuOlY2QDFizszN MWLTRW5ITVJ?
UACC-812 M1jCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f5TmlEPTB;ND62PVE3OSEQvF2= MXjTRW5ITVJ?
CTB-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjVOo43UUN3ME20MlcyPTV3IN88US=> NX70ZoxVW0GQR1XS
ALL-PO NX75[XBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fuSmlEPTB;ND64OFA4PyEQvF2= NWH1VXlLW0GQR1XS
SK-MEL-2 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\p[lZKSzVyPUSuPFY6PTVizszN MYHTRW5ITVJ?
TC-YIK NWTtTotXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRwOUe5OFIh|ryP NHXjZXdUSU6JRWK=
NCI-H1882 NH\mcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjuVllKSzVyPUWuNFIxODFizszN NIT2e5JUSU6JRWK=
MHH-CALL-2 M2j6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\2TpdTUUN3ME21MlA2ODR{IN88US=> M1XkWnNCVkeHUh?=
U-87-MG Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvP[YJOUUN3ME21MlA6PDZ4IN88US=> M2TYSHNCVkeHUh?=
NCI-H1092 NYLkNnR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[yNlhKSzVyPUWuNlY2PTVizszN M1ThNHNCVkeHUh?=
TE-441-T Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPWNVMxUUN3ME21MlI4QDJizszN MnLzV2FPT0WU
SK-MEL-1 NFzRcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO1TWM2OD13LkK5NFQ1KM7:TR?= M4nCeXNCVkeHUh?=
EW-22 NY\BWI5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7sTWM2OD13LkK5OFY3KM7:TR?= MX\TRW5ITVJ?
MZ7-mel M3HaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn0bXJKSzVyPUWuOFA3QTFizszN MXjTRW5ITVJ?
LP-1 NWTDOG93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zlXWlEPTB;NT60NVI6OSEQvF2= M1rENXNCVkeHUh?=
NCI-SNU-16 NXjEXFZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrCTWM2OD13Lk[0NFc1KM7:TR?= MlfGV2FPT0WU
LU-65 NYDrZo9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jZN2lEPTB;NT63OlM4OyEQvF2= MVTTRW5ITVJ?
CW-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1frWGlEPTB;NT64OVk2QSEQvF2= NHf1NYpUSU6JRWK=
WSU-NHL M4TzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[1bnViUUN3ME21Mlk2OTd2IN88US=> NWLWbI41W0GQR1XS
IST-MES1 M1;4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\QTWM2OD13Lkm1OFQ{KM7:TR?= NH7GfFNUSU6JRWK=
U-266 Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17MfWlEPTB;NT65PFIxOiEQvF2= M1vFRXNCVkeHUh?=
TALL-1 NXrIVo92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DYXGlEPTB;Nj6xOFY5QCEQvF2= NFzwXI1USU6JRWK=
Calu-6 M33jeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvtTWM2OD14LkG1N|E3KM7:TR?= MWjTRW5ITVJ?
MMAC-SF MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPMTWM2OD14LkG4OVU3KM7:TR?= NH33V5ZUSU6JRWK=
NCI-H82 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HRXmlEPTB;Nj6yNFQ5QSEQvF2= M1:1d3NCVkeHUh?=
RS4-11 MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrxZ417UUN3ME22MlI2QDl5IN88US=> MYnTRW5ITVJ?
SNU-C2B MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTZwNEC5Olkh|ryP NVW1SlZiW0GQR1XS
BOKU MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn63TWM2OD14LkS3OVk4KM7:TR?= MkK1V2FPT0WU
C8166 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPkfVhKSzVyPU[uOVU6OTJizszN MXLTRW5ITVJ?
D-247MG M4HuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorZTWM2OD15LkC0N|Q4KM7:TR?= MlLzV2FPT0WU
EW-18 NIrPXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDGSY1KSzVyPUeuNFczQTJizszN NHjtc5ZUSU6JRWK=
KG-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofjTWM2OD15Lk[yO|M5KM7:TR?= MoTyV2FPT0WU
REH MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfZTWM2OD15Lk[4NVA6KM7:TR?= NFfYR2VUSU6JRWK=
U-698-M MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DEPWlEPTB;Nz64OFMyPSEQvF2= MnPQV2FPT0WU
KP-N-RT-BM-1 NU\uWWtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTdwOUOwNlkh|ryP NVrTVGVEW0GQR1XS
MS-1 M125[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7uTWM2OD15Lkm2NFQyKM7:TR?= MkPlV2FPT0WU
SNU-C1 M37QU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTdwOUixPVIh|ryP MVjTRW5ITVJ?
SK-MM-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW4TWM2OD16LkK2NFY2KM7:TR?= NHzLbnBUSU6JRWK=
LAN-6 MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n1OmlEPTB;OD6zNFAxOSEQvF2= NXi2UIlrW0GQR1XS
NEC8 M{Kwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRThwM{C2PVEh|ryP NX7VToJsW0GQR1XS
NCI-H1770 M2XWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7R[3pKSzVyPUiuN|gxODJizszN M1[4SHNCVkeHUh?=
D-336MG M1:yPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPOVYp[UUN3ME24MlQxOTF4IN88US=> Mk[xV2FPT0WU
COLO-829 M4jHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rH[GlEPTB;OD60PFg4QSEQvF2= NU[zcXBoW0GQR1XS
LS-513 NVi2flZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnnTWM2OD16LkW5OVk6KM7:TR?= Mn7RV2FPT0WU
YT MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvPfWZKSzVyPUiuOlI1OjdizszN M13iXnNCVkeHUh?=
EW-24 NGTKO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7jTWM2OD16Lke2OVQh|ryP Mli3V2FPT0WU
IST-SL1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\JSmlEPTB;OD64OlU1OyEQvF2= NWHnXJppW0GQR1XS
CA46 NICyPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXRdnJKSzVyPUiuPVUxQThizszN MXvTRW5ITVJ?
NCI-H1838 M4nRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThwOUi2NFIh|ryP NIfOTFNUSU6JRWK=
NCI-H719 M{DxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjKWnZKSzVyPUmuNlUzPzlizszN MUTTRW5ITVJ?
HCE-T NV7SfGl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD2blM6UUN3ME25MlMxQDVzIN88US=> M3jFT3NCVkeHUh?=
A498 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3IXGFKSzVyPUmuN|YyOjRizszN MY\TRW5ITVJ?
LB831-BLC M1m0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTlwN{[1NlEh|ryP NILJOG5USU6JRWK=
SKM-1 NUj2NHdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjPTWM2OD17Lki1PVY{KM7:TR?= MXLTRW5ITVJ?
THP-1 M2LMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHDTWM2OD17Lkm2PVE5KM7:TR?= MXzTRW5ITVJ?
SHP-77 M1TFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO5[mRTUUN3ME2xNE41ODdizszN MmTVV2FPT0WU
EW-3 NITnTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\CbGlEPTB;MUCuOlI5QSEQvF2= MVHTRW5ITVJ?
KY821 NUnQc2pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFyLke2N{DPxE1? MorXV2FPT0WU
NCI-SNU-1 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfrTWM2OD1zMT6wNlE4KM7:TR?= NX7mepVzW0GQR1XS
HCC2218 Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvjelVKSzVyPUGxMlM6QDZizszN NWK3SFNzW0GQR1XS
IM-9 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvwb4xKSzVyPUGxMlUyODZizszN M{W4eXNCVkeHUh?=
NCI-H889 NUe4ZnVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoKwTWM2OD1zMT61N|E{KM7:TR?= NFXYc49USU6JRWK=
HDLM-2 Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF{LkSxOVkh|ryP MUTTRW5ITVJ?
LB2518-MEL NUHwXI4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPwNJBKSzVyPUGyMlY5OTVizszN MnH2V2FPT0WU
NCI-H23 M1rUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zzcmlEPTB;MUOuNlQzPSEQvF2= NEXYdGpUSU6JRWK=
NB17 NHntdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\5OY9ZUUN3ME2xN{41PTd7IN88US=> M3LCWHNCVkeHUh?=
NCI-H322M NH;tTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHVRVl7UUN3ME2xOE41ODZ6IN88US=> MnK3V2FPT0WU
SUP-T1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrkNHNKSzVyPUG0MlQyOyEQvF2= MXzTRW5ITVJ?
ES3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfwTWM2OD1zNT6wO|A{KM7:TR?= NIXITY1USU6JRWK=
ES5 NWHkbHlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjqOoZLUUN3ME2xOU4xPzh5IN88US=> MnPOV2FPT0WU
NCI-H1650 MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF3LkS5O|kh|ryP MmTIV2FPT0WU
NCI-H226 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF3Lki3Olgh|ryP NH3WWGxUSU6JRWK=
COR-L88 NVPDPZl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonYTWM2OD1zNj6zNVQh|ryP NG\Vc|FUSU6JRWK=
SCC-15 NG\scZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjTbmc3UUN3ME2xOk4{QDZ7IN88US=> M4L2VnNCVkeHUh?=
GOTO MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTITWM2OD1zNj60O|k{KM7:TR?= M2XLV3NCVkeHUh?=
SIMA NXe5fZpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF4LkS4NFIh|ryP NUX3XYJ{W0GQR1XS
NCI-H1299 M4DuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF5LkG1PVEh|ryP MXnTRW5ITVJ?
NCI-H1581 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF5LkSyNVkh|ryP NWLmVZBQW0GQR1XS
MHH-NB-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlryTWM2OD1zNz65Olg{KM7:TR?= MW\TRW5ITVJ?
MFM-223 NVHzWVg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jpPWlEPTB;MUiuNFU{QCEQvF2= NFfsXHpUSU6JRWK=
ES7 NVzhZ4dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[3d|BuUUN3ME2xPE42PDNzIN88US=> NVPv[Y1QW0GQR1XS
JVM-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH74T5dKSzVyPUG4MlcyPyEQvF2= M1vwU3NCVkeHUh?=
RL MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJyLkO4PEDPxE1? M1LpWnNCVkeHUh?=
EC-GI-10 NXPNXY9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDWNooxUUN3ME2yNU4zODRzIN88US=> NWO4RnFkW0GQR1XS
LNCaP-Clone-FGC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJzLk[3Olgh|ryP MX7TRW5ITVJ?
IMR-5 M13C[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LxdGlEPTB;MkGuPFQ6PCEQvF2= MY\TRW5ITVJ?
KP-N-YS NX7wdGFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Lmc2lEPTB;MkGuPFc2KM7:TR?= MWfTRW5ITVJ?
Mo-T Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XJO2lEPTB;MkKuNlE5PSEQvF2= MXLTRW5ITVJ?
NCI-H128 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ|LkW4OVMh|ryP NYPDe3NOW0GQR1XS
RH-1 NWT3fIRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJ|Lke4OlYh|ryP NGPNcppUSU6JRWK=
NCI-H2171 MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXkTWM2OD1{ND6yOFg2KM7:TR?= MkH5V2FPT0WU
RPMI-8866 NXPkPJhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ4Lke0NkDPxE1? NGjjfGtUSU6JRWK=
SK-N-FI NGrvcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfoeno6UUN3ME2yO{4{QDFzIN88US=> NV;JencxW0GQR1XS
LOXIMVI M3jwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX2TWM2OD1{Nz64NFUyKM7:TR?= MmH0V2FPT0WU
P31-FUJ M{Lpe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\lcJdQUUN3ME2zNU42Ozd2IN88US=> NVXaWJZ1W0GQR1XS
KMS-12-PE NWi3cIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vyNmlEPTB;NEmuOVMxOiEQvF2= NX\JfYxWW0GQR1XS

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞試験:

[3]

+ 展開
  • 細胞株: U87-MG, T98G, and U373-MG
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • 製剤: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • 投薬量: ~4 mg/kg/day
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管
in solvent
別名 AY 22989,NSC-2260804

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00977691 Active not recruiting Peripheral Blood Stem Cell Transplantation|Anemia Sickle Cell|Graft-Versus-Host Disease|Sirolimus (Rapamune )|Alemtuzumab (Campath ) National Heart Lung and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) September 9 2009 Phase 1|Phase 2
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9 2003 Phase 2
NCT02833506 Withdrawn Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI) December 8 2017 Phase 1
NCT01885689 Active not recruiting Adult Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia in Remission|Myelodysplastic Syndrome|Secondary Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Therapy-Related Myelodysplastic Syndrome City of Hope Medical Center|National Cancer Institute (NCI) January 8 2014 Phase 2
NCT01869114 Recruiting Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Myelodysplastic Syndrome With Isolated Del(5q)|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University July 8 2013 Phase 2
NCT01363752 Completed Kidney Transplantation Astellas Pharma Inc March 8 2011 Phase 4

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

mTORシグナル伝達経路

mTOR Inhibitors with Unique Features

相関mTOR製品

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)化学構造 | Rapamycin (Sirolimus)分子量 | Rapamycin (Sirolimus)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID